The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,372.00
Bid: 12,372.00
Ask: 12,376.00
Change: 40.00 (0.32%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS -Vaccine hopes lift world stocks, but caution creeps in

Mon, 14th Sep 2020 12:30

* AstraZeneca resumes phase-3 trial for coronavirus vaccine

* UK, US, Japan central banks meet this week

* Japan's Suga wins ruling party leadership race

* UK parliament to vote on plan to break Brexit divorce
treaty

* Graphic: 2020 asset performance http://tmsnrt.rs/2yaDPgn

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh
(Recasts to reflect shift in sentiment, updates market moves,
adds comment)

By Dhara Ranasinghe

LONDON, Sept 14 (Reuters) - World stocks nudged higher on
Monday on hopes for a coronavirus vaccine after AstraZeneca
resumed its phase-3 trial, but the gains were limited as caution
prevailed before a host of central bank meetings this week.

Sterling, which has been hurt by renewed Brexit turmoil,
firmed before a key vote on British Prime Minister Boris
Johnson's plan to break international law by breaching parts of
the Brexit divorce treaty with the European Union.

European stock markets opened higher but drifted
back down. U.S. stock futures held firm in a
positive sign for the Wall Street open, supported by M&A news.

In Asia, MSCI's broadest index of Asia-Pacific shares
outside Japan rose 0.9% to its highest in almost
a week. Japan's Nikkei firmed 0.7% after Chief Cabinet
Secretary Yoshihide Suga won a landslide victory in a ruling
party leadership election, paving the way for him to succeed
Prime Minister Shinzo Abe.

Drugmaker AstraZeneca said at the weekend it has
resumed British clinical trials of its COVID-19 vaccine, one of
the most advanced in development, after getting the green light
from safety watchdogs.

The World Health Organization reported a record one-day
increase in global coronavirus cases on Sunday, with the total
rising by 307,930 in 24 hours. The biggest increases were from
India, the United States and Brazil.

"There is still some caution in markets because U.S. virus
numbers appear to be picking up again in some states," said
Seema Shah, chief strategist at Principal Global Investors.

"The vaccine is positive news but there is a lot of
scepticism about when it comes in and how widely it will be
adopted."

And as the European session wore on, some markets gave up
their gains and turned negative .

Upcoming central bank meetings in the United States, Britain
and Japan added to a sense of caution.

The U.S. Federal Reserve on Tuesday kicks off a two-day
policy meeting -- the first since unveiling its landmark shift
to a more tolerant stance on inflation last month. The Bank of
Japan and the Bank of England will announce their respective
policy decisions on Thursday.

BREXIT WATCH

In currency markets, sterling bounced off recent 1-1/2 month
lows against the dollar ahead of a parliamentary debate
on the Internal Market Bill. After the debate, lawmakers will
vote to decide if it should go to the next stage.

Johnson's decision to explicitly break international law has
plunged Brexit back into crisis less than four months before
Britain is finally due to leave the EU's orbit at the end of a
post-Brexit transition period.

"The question will be how many Conservative MPs (members of
parliament) rebel on the matter," said Deutsche Bank strategist
Jim Reid, referring to Johnson's ruling party.

The dollar was a tad weaker at 105.95 yen, though
still a long distance from its low this year of 101.2. The euro
was a fifth of a percent firmer at $1.1870.

Turkey's lira hit a fresh record low against the U.S. dollar
and its dollar-bonds came under pressure after Moody's
cut the country's sovereign rating and warned of the risk of a
balance of payment crisis.

Oil prices fell, weighed down in part by Libya signaling it
would end its months-long blockade and resume output, adding yet
more supply to the market.

Brent crude was down 0.5% at $39.62 a barrel while
U.S. West Texas Intermediate (WTI) crude futures slipped
0.6% to $37.11 a barrel.

Gold meanwhile was a touch firmer at at $1,943.72 per
ounce.

(Reporting by Dhara Ranasinghe; Editing by Peter Graff and
Bernadette Baum)

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.